A new study reveals what has happened in several areas of healthcare delivery following the ACA Medicaid expansion.
Mazurenko
Medicaid expansion following the ACA was associated with increases in coverage, service use, quality of care, and Medicaid spending, according to a new study.
In a systematic literature review, published in Health Affairs, lead study author Olena Mazurenko, MD, PhD, of Indiana University, and colleagues, analyzed 77 studies and conducted the systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Very few studies reported that Medicaid expansion was associated with negative consequences, such as increased wait times for appointments, according to the researchers.
“Thus, there is evidence to document improvements in several areas of healthcare delivery following the ACA Medicaid expansion,” says Mazurenko, who is assistant professor, Department of Health Policy and Management, Indiana University in Indianapolis.
The researchers observed significant differences in the likelihood of reporting an effect that was inconsistent with the ACA based on the study design. Specifically, studies with stronger designs (for example, experimental or quasi-experimental studies) did not differ from other studies (for example, cross-sectional or uncontrolled studies) with respect to the likelihood of reporting a relationship consistent with the ACA.
“However, study designs with weaker internal validity were significantly more likely to report an effect inconsistent with the ACA,” Mazurenko says. “For example, Chang-Yeon Kim reported a decrease in access to care based on cross-sectional data and using a study design not suited for attributing causality. Thus, our synthesis of results presented in the literature review focused exclusively on studies that used quasi-experimental designs.”
Based on the study, Mazurenko has three takeaways for healthcare executives:
“Managed care executives can learn from our study that the current best evidence on the ACA’s Medicaid expansion suggests that improvements in access to and quality of care, as well as to some degree in health, have occurred,” she says. “More research is needed to understand the impact of this major policy decision fully.”
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
Extending the Capabilities of the EHR Through Automation
August 2nd 2023Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More